证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | --- | |-------------------------|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------| | | ☑ 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他：线上交流活动 | | | 参与单位名称及 人员姓名 | 诺安基金——王晴 | | | 时间 | 2022 年 11 月 10 日（周四） | 14:00 — 15:00 | | 地点 | 公司大会议室 | | | 上市公司 ...

，证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | --- | |-------------------------|---------------------------------------|------------------------------------------------------------------------------------------------------------| | | ☑ 特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他：线上交流活动 | | | 参与单位名称及 人员姓名 | 东北证券——莫然 汇丰普信基金——赵洋 | | | 时间 | 2022 年 11 月 11 日（周五） | 10:00 — 11:00 | | 地点 | 公司大会议室 | | | 上市公司接待人 员姓名 | 董事会秘书—杨高锋 证券事务助理—叶骏超 ...

证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |-------------------------|---------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ☑ 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他：线上交流活动 | | | 参与单位名称及 人员姓名 | 常春藤 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥233,861,160.04, representing a 21.58% increase compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was ¥28,254,137.51, up 38.76% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥25,907,474.27, an increase of 31.07% compared to the previous year[5] - The basic earnings per share for Q3 2022 was ¥0.15, a 15.38% increase year-on-year[5] - Net profit for Q3 2022 was ¥88,248,593.08, representing a growth of 8.1% from ¥81,597,542.92 in Q3 2021[25] - Earnings per share (EPS) for Q3 2022 was ¥0.43, a decrease from ¥0.51 in the same quarter last year[26] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥2,364,710,525.62, reflecting a 4.45% increase from the end of the previous year[5] - The total equity attributable to shareholders at the end of Q3 2022 was ¥1,577,427,986.85, a 4.47% increase from the previous year-end[5] - The total liabilities increased to ¥706,767,066.75 from ¥678,549,169.20 year-over-year, reflecting a rise of 4.3%[25] - The total current liabilities increased to CNY 548,738,504.39 from CNY 489,890,389.72, showing an increase of approximately 11.9%[21] - Long-term borrowings decreased to CNY 125,180,446.82 from CNY 164,530,563.84, indicating a reduction of about 23.9%[21] Cash Flow - The cash flow from operating activities for the year-to-date period decreased by 63.25% to ¥53,983,974.44[5] - Cash flow from operating activities generated a net amount of ¥53,983,974.44, down from ¥146,886,818.39 in Q3 2021[27] - The company reported a net cash outflow from investment activities of CNY 277.17 million, a 43.25% increase compared to the previous year[12] - The cash inflow from operating activities totaled ¥771,067,723.75, compared to ¥750,626,699.29 in the previous year, indicating a slight increase of 2.9%[27] - The net cash flow from investment activities was -¥277,168,363.78, compared to -¥193,488,810.70 in the previous year, indicating a decline of approximately 43.4%[29] - The total cash inflow from financing activities was ¥107,846,149.07, a significant decrease of 87.2% from ¥839,813,241.73 in the same period last year[29] - The net cash flow from financing activities was -¥82,212,385.12, contrasting sharply with a positive net flow of ¥660,481,320.43 in the previous year[29] Investments and Expenses - Research and development expenses grew by 48.46% to CNY 30.89 million, reflecting increased investment in R&D[11] - Research and development expenses increased to ¥30,889,093.53, a rise of 48.5% compared to ¥20,806,731.30 in the previous year[24] - The company reported a decrease in financial expenses, showing a net income of -¥11,449,385.79 compared to a positive income of ¥2,730,833.43 in Q3 2021[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,064[14] - The largest shareholder, Lin Wuhui, holds 29.98% of the shares, amounting to 58,019,499 shares[14] Other Information - The company received government subsidies amounting to ¥3,286,844.22 during the reporting period[6] - The company issued convertible bonds on July 14, 2022, which were accepted by the Shenzhen Stock Exchange, indicating a strategic move to raise capital[17] - The company responded to an inquiry from the Shenzhen Stock Exchange regarding the issuance of convertible bonds on August 9, 2022, demonstrating proactive communication with regulators[17] - The company is actively engaged in the development of new products and technologies, although specific details were not disclosed in the report[19] - The company did not conduct an audit for the third quarter report, as indicated in the audit report section[30] - The company experienced a foreign exchange impact on cash and cash equivalents of ¥5,989,649.77, compared to -¥319,017.85 in the previous year[29]

Financial Performance - The company reported a revenue of 300 million RMB for the first half of 2022, representing a year-on-year increase of 15%[13] - The company's revenue for the reporting period was ¥480,135,188.73, representing an increase of 11.93% compared to ¥428,971,227.44 in the same period last year[19] - The company achieved operating revenue of 48,013.52 million yuan, representing a year-on-year growth of 11.93%[37] - The company reported a total revenue of 8.9 million yuan, indicating a significant change in financial performance[170] - The total revenue for the first half of 2022 was 1,347.4 million yuan, showing an increase compared to the previous year's 638.6 million yuan, representing a growth of approximately 110%[173] Profitability - Net profit attributable to shareholders decreased by 6.14% to ¥55,021,006.98 from ¥58,620,084.28 year-on-year[19] - The company reported a net profit of CNY 58,662,833.57, a decrease of 3.0% from CNY 60,417,659.66 in the previous year[154] - The company's total comprehensive income for the first half of 2022 was CNY 1,652,652.23, reflecting a decrease of 59.2% compared to CNY 4,047,487.32 in the previous year[158] - The net profit for the first half of 2022 was CNY 1,652,652.23, down 59.2% from CNY 4,047,487.32 in the first half of 2021[158] - Basic and diluted earnings per share fell by 24.32% to ¥0.28 from ¥0.37 in the same period last year[19] Research and Development - The company plans to invest 50 million RMB in R&D for new packaging technologies in the upcoming year[13] - R&D investment grew by 51.63% year-on-year, with 25 new patents and 13 new drug packaging material registration numbers added in the first half of the year[38] - The company's research and development investment increased by 51.63% to ¥23,287,264.65, up from ¥15,358,153.17, reflecting a stronger focus on product development[44] - The company is focusing on the development of high-barrier, low-adsorption, and low-migration packaging materials for the pharmaceutical industry, enhancing its product range and market competitiveness[27] - The company is committed to continuous technological innovation and product structure adjustment to enhance core competitiveness in response to market challenges[71] Market Expansion - User data indicates a 20% increase in customer base, reaching 1,200 active clients[13] - The company has expanded its market presence in Europe, with sales in that region growing by 25%[13] - The company is actively expanding its overseas business, with foreign sales and procurement primarily in USD and EUR, exposing it to exchange rate risks[74] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not mentioned in the provided data[164] - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[171] Financial Position - The total assets increased by 4.78% to ¥2,372,186,518.46 from ¥2,264,050,337.46 at the end of the previous year[19] - The company's cash and cash equivalents decreased significantly by 2,800.40% to -¥213,633,295.93, compared to an increase of ¥7,911,159.66 in the previous year[45] - The company's total assets at the end of the reporting period amounted to 823.9 million yuan, up from 263.2 million yuan in the same period last year, indicating a growth of about 213%[176] - The total equity attributable to owners at the end of the period was 1,333.29 million yuan, up from 638.6 million yuan in the previous year, representing an increase of approximately 108%[175] - The company's total liabilities rose from CNY 678,549,169.20 to CNY 743,825,132.01, reflecting an increase of approximately 9.63%[146] Cash Flow - The net cash flow from operating activities dropped significantly by 76.69%, amounting to ¥19,995,507.24 compared to ¥85,782,233.76 in the previous year[19] - Cash flow from operating activities generated a net amount of CNY 19,995,507.24, a significant decline of 76.7% compared to CNY 85,782,233.76 in the previous year[159] - The company reported a net cash outflow from investing activities of CNY 215,006,579.10, compared to a net outflow of CNY 120,513,113.78 in the same period last year[161] - The cash flow from financing activities showed a net outflow of CNY 22,041,202.89, contrasting with a net inflow of CNY 43,122,313.73 in the first half of 2021[161] - The total cash inflow from financing activities was CNY 33,868,200.38, up from CNY 28,570,000.00 in the previous period, while cash outflows were CNY 52,910,445.49, down from CNY 61,909,610.98[164] Strategic Initiatives - The company is exploring potential acquisitions to enhance its product offerings and market reach[13] - The company has made strategic acquisitions, including a 68% stake in Duoling Pharmaceutical Packaging in August 2016 and a 100% stake in Suzhou Qingyi in March 2017, enhancing market presence and profitability[73] - The company is focusing on strategic mergers and acquisitions to strengthen its market presence[171] - The company aims to improve operational efficiency through policy changes and error corrections in financial reporting[171] - The company has initiated a new technology research and development program aimed at improving packaging materials[171] Corporate Governance - The company adheres to legal regulations and has improved its corporate governance structure to protect shareholder rights, ensuring accurate and timely information disclosure[93] - The company has implemented a stable profit distribution policy to secure shareholder returns and has no instances of major shareholders or related parties misusing company funds during the reporting period[93] - The company actively engages in investor relations management, utilizing multiple channels to enhance investor awareness and protect their rights[95] - The company has confirmed that there are no significant doubts regarding its ability to continue as a going concern for the next 12 months[181] - The financial statements are prepared in accordance with the enterprise accounting standards, reflecting the company's financial position, operating results, and cash flows accurately[183] Environmental and Social Responsibility - The company has no environmental penalties during the reporting period and adheres to national and local environmental regulations[89] - The company is committed to sustainable development, focusing on economic benefits while fulfilling social responsibilities[92] - The company has implemented measures to reduce carbon emissions, including the use of low-nitrogen burners and waste gas treatment systems[91] - The company has participated in charitable activities, including donations to educational institutions, while balancing economic benefits with social responsibilities[96] - The company emphasizes the importance of integrating corporate culture and management systems post-acquisition to realize expected investment returns[73]

Financial Performance - Revenue for Q1 2022 was CNY 231,871,055.84, an increase of 3.57% compared to CNY 223,874,529.01 in the same period last year[4] - Net profit attributable to shareholders decreased by 24.13% to CNY 25,483,174.76 from CNY 33,586,697.68 year-on-year[4] - Basic earnings per share fell by 38.10% to CNY 0.13 from CNY 0.21 in the same period last year[4] - The net profit for Q1 2022 was CNY 27,050,277.66, a decrease of 21.1% from CNY 34,217,622.40 in Q1 2021[24] - The profit attributable to the parent company's shareholders was CNY 25,483,174.76, down 24.2% from CNY 33,586,697.68 in the previous year[24] - The total comprehensive income for the first quarter was CNY 27,050,277.66, a decrease from CNY 34,217,622.40 in the previous year, representing a decline of approximately 21%[25] Cash Flow and Liquidity - Net cash flow from operating activities was negative at CNY -39,061,737.17, a decline of 209.64% compared to CNY 35,626,124.72 in the previous year[4] - Cash inflow from operating activities totaled CNY 179,921,854.94, down from CNY 219,412,068.25, indicating a decrease of about 18%[27] - The company reported cash outflows from operating activities of CNY 218,983,592.11, an increase of approximately 19% from CNY 183,785,943.53 in the previous year[27] - The cash and cash equivalents at the end of the period were CNY 435,806,092.42, a significant increase of 358.06% from CNY 95,140,921.56 at the end of the previous year[9] - The company reported cash and cash equivalents of ¥457,017,550.08 at the end of the period, down from ¥633,853,715.33 at the beginning of the year[17] Assets and Liabilities - Total assets increased by 2.35% to CNY 2,317,309,669.68 from CNY 2,264,050,337.46 at the end of the previous year[4] - The total liabilities increased to CNY 697,322,406.15, up from CNY 678,549,169.20, representing a rise of 2.3%[19] - The inventory level was CNY 162,539,558.44, slightly up from CNY 160,744,669.02, showing a marginal increase of 1.1%[18] Investment Activities - Investment activities generated a net cash outflow of CNY -129,754,726.70, an increase of 103.68% compared to CNY -63,704,263.81 in the previous year[9] - The total cash inflow from investment activities was CNY 36,485,924.01, down from CNY 55,361,561.05, indicating a decline of about 34%[27] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,934[11] - The largest shareholder, Lin Wuhui, holds 29.98% of shares, totaling 58,019,499 shares, with 9,800,000 shares pledged[11] - The top ten shareholders include Zhu Xiumei with 16.65% ownership, totaling 32,230,408 shares[11] - The total number of restricted shares at the end of the period is 68,494,869, with 1,379,250 shares released and 429,750 shares newly restricted during the period[15] - The company has a total of 69,444,369 restricted shares, with various executives holding significant amounts[15] Operational Insights - The company is focused on expanding its market presence and developing new products in the pharmaceutical packaging sector[12] - The management emphasizes the importance of innovation in product development to maintain competitive advantage[12] - The company plans to continue its strategy of shareholder engagement and potential future capital raises[12] Costs and Expenses - The total operating costs for Q1 2022 amounted to CNY 201,369,862.48, up 8.5% from CNY 185,596,469.38 year-over-year[22] - Research and development expenses for Q1 2022 were CNY 7,732,996.71, an increase of 26.0% from CNY 6,138,998.03 in the same period last year[22] - The company reported a financial cost of CNY -1,904,352.15, which is a decrease compared to CNY -803,402.29 in the previous year, indicating improved financial management[22] - The company reported a significant increase in cash paid for purchasing goods and services, totaling CNY 151,465,112.46, compared to CNY 127,487,870.31 in the previous year, an increase of approximately 19%[27] Credit and Impairment - The company experienced a 2959.03% increase in credit impairment losses, amounting to CNY -1,901,408.34, primarily due to increased bad debt provisions[8]

Financial Performance - The company's operating revenue for 2021 was ¥856,857,795.71, representing a 20.04% increase compared to ¥713,784,961.63 in 2020 [17]. - The net profit attributable to shareholders for 2021 was ¥104,645,765.20, a slight increase of 1.69% from ¥102,903,824.33 in 2020 [17]. - The total assets at the end of 2021 reached ¥2,264,050,337.46, marking a 61.09% increase from ¥1,405,486,674.79 at the end of 2020 [17]. - The net assets attributable to shareholders increased by 87.52% to ¥1,509,959,144.83 at the end of 2021, compared to ¥805,246,111.02 at the end of 2020 [17]. - The company reported a basic earnings per share of ¥0.64 for 2021, down 4.48% from ¥0.67 in 2020 [17]. - The company achieved a revenue of ¥856,857,795.71 in 2021, representing a 20.04% increase compared to the previous year [42]. - Net profit for the year was ¥109,029,338.38, up 3.42% year-over-year, with net profit attributable to the parent company at ¥104,645,765.20, an increase of 1.69% [42]. - Total revenue for 2021 reached ¥856,857,795.71, representing a year-on-year increase of 20.04% compared to ¥713,784,961.63 in 2020 [49]. - Revenue from new pharmaceutical packaging materials was ¥763,128,525.11, accounting for 89.06% of total revenue, with a year-on-year growth of 17.44% [49]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15% [131]. Cash Flow and Investments - The net cash flow from operating activities increased significantly by 80.21% to ¥139,639,384.21 in 2021, compared to ¥77,485,971.77 in 2020 [17]. - Operating cash inflow increased by 42.96% to ¥995,885,747.19, while operating cash outflow rose by 38.30% to ¥856,246,362.98, resulting in a net cash flow of ¥139,639,384.21, an increase of 80.21% [68]. - Net cash flow from financing activities surged by 1,124.46% to ¥653,496,880.86, primarily due to funds raised from issuing shares to specific investors [69]. - The company's cash and cash equivalents increased significantly by 3,414.59% to ¥542,856,652.19 [69]. - The cash flow from investment activities showed a net outflow of ¥248,677,350.05, a 120.31% increase in outflow compared to the previous year [69]. - The company successfully raised ¥601 million through a private placement to enhance capital strength and support capacity expansion [45]. - The company utilized CNY 6,957.56 million of the raised funds in 2021, with a remaining balance of CNY 52,955.04 million yet to be used [79]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1.20 RMB per 10 shares (including tax) to all shareholders, based on a total share capital of 193,531,505 shares [4]. - The cash dividend represents 100% of the total profit distribution amount [154]. - The company has a profit distribution policy that aligns with its articles of association and shareholder resolutions [154]. - The company plans to distribute a cash dividend of RMB 1.2 per 10 shares, totaling RMB 23,223,780.60 for the year 2021 [156]. - The company's available distributable profits amount to RMB 445,586,706.81 [154]. Market Position and Strategy - The domestic pharmaceutical packaging industry has stabilized with a market size exceeding ¥100 billion, maintaining good growth momentum [28]. - The company is positioned to benefit from government policies that support the high-quality development of the pharmaceutical packaging industry [28]. - The company is actively expanding into new markets, including new consumption and new energy sectors, to create new growth points [42]. - The company aims to leverage the growing Chinese plastic packaging industry, which is benefiting from the rapid growth of the cosmetics sector, by expanding its footprint in consumer goods packaging [94]. - The company is implementing a "four-wheel drive" development strategy to enhance its core pharmaceutical packaging business while exploring new segments such as new consumption, new energy, and recyclable high barrier composite materials [95]. - The company plans to expand its production capacity to 1,500 tons of high barrier and high seal pharmaceutical packaging composite film annually following a capital increase of 46.75 million CNY in Zhejiang Duoling Pharmaceutical Packaging Materials Co., Ltd. [93]. Research and Development - R&D investment increased by 35.33% during the reporting period, focusing on innovation to enhance product quality and expand product series [43]. - The company has 109 patents, including 13 invention patents, and focuses on continuous R&D investment to meet high-performance requirements from downstream pharmaceutical clients [37]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficiency and sustainability [112]. - The company has developed new products such as high-barrier easy-peel thermoforming sheets and corrosion-resistant lithium battery aluminum-plastic films, expanding its application in new consumption and new energy sectors [34]. Risk Management - The company faces various risks including market competition, raw material price fluctuations, macroeconomic policy risks, and integration risks from mergers and acquisitions [4]. - Raw material prices, particularly aluminum and petroleum derivatives, significantly impact production costs, and the company will manage inventory and diversify procurement channels to mitigate risks from price fluctuations [104]. - The company is exposed to foreign exchange risks due to international sales and procurement, primarily in USD and EUR, and will manage import-export operations to mitigate these risks [108]. Corporate Governance - The company emphasizes transparency in information disclosure, utilizing multiple media outlets to ensure equal access to information for all shareholders [117]. - The company maintains independence from its controlling shareholders, ensuring no interference in decision-making or operations [117]. - The company has established a comprehensive welfare system, including social insurance and housing funds, to support employee well-being [150]. - The company has a governance structure that does not include any differential voting rights arrangements [123]. - The company has a long-term commitment to fulfill all obligations related to social security and housing fund policies, ensuring compliance and financial accountability [182]. Environmental Responsibility - The company adheres to environmental regulations, with no administrative penalties related to environmental issues during the reporting period [171]. - The company's environmental protection facilities operated normally, ensuring compliance with national and local environmental laws [171]. - The company has established a comprehensive waste management system, ensuring that solid waste is properly stored and pollutants are treated according to standards [172]. - During the reporting period, the company implemented various pollution prevention measures, including the treatment of exhaust gases through advanced filtration systems [173]. Employee Engagement and Compensation - The company has implemented a stock incentive plan covering 67 core personnel to retain talent and enhance employee engagement amid industry competition [107]. - The total remuneration paid to the board of directors, supervisors, and senior management for the year 2021 amounted to CNY 4.3398 million [135]. - The basic annual salary for senior management is determined based on the importance of the position, industry salary levels, and individual qualifications [136]. - The company provides competitive salaries based on market principles and performance evaluations, with a focus on retaining talent [150].

上海海顺新型药用包装材料股份有限公司 2021 年第三季度报告 证券代码：300501 证券简称：海顺新材 公告编号：2021-066 上海海顺新型药用包装材料股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 192,346,333.70 | 14.94% | 621,317,561 ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥428,971,227.44, representing a 31.45% increase compared to ¥326,337,482.68 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥58,620,084.28, up 24.36% from ¥47,136,833.09 in the previous year[21]. - Basic earnings per share rose to ¥0.37, a 23.33% increase from ¥0.30 in the previous year[21]. - The company achieved operating revenue of 428.97 million yuan, a year-on-year increase of 31.45%[45]. - The net profit attributable to shareholders was 58.62 million yuan, reflecting a year-on-year growth of 24.36%[36]. - The total profit for the first half of 2021 was ¥69,441,681.80, compared to ¥55,598,647.56 in the first half of 2020, marking a 24.8% increase[149]. - The total comprehensive income for the current period amounted to CNY 60.42 million, reflecting a significant increase compared to the previous period[164]. Cash Flow - The net cash flow from operating activities increased by 70.06%, reaching ¥85,782,233.76 compared to ¥50,443,377.22 in the same period last year[21]. - The net cash flow from operating activities for the first half of 2021 was ¥85,782,233.76, an increase of 70% compared to ¥50,443,377.22 in the same period of 2020[157]. - The net cash flow from financing activities was ¥43,122,313.73, a significant improvement from -¥40,236,486.71 in the first half of 2020[158]. - The ending cash and cash equivalents balance was ¥78,515,117.22, compared to ¥46,098,157.29 at the end of the first half of 2020, marking an increase of about 70%[158]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,567,239,556.45, an increase of 11.51% from ¥1,405,486,674.79 at the end of the previous year[21]. - Total liabilities amounted to CNY 628,521,394.30, compared to CNY 529,082,113.52, indicating a rise of around 18.8%[141]. - The company's total liabilities at the end of the current period were CNY 265.30 million[164]. - The company's total assets at the end of the period amounted to 1,138,548,431.45 CNY, indicating a significant financial position[166]. Research and Development - Research and development investment increased by 33.45% to 15.36 million yuan, emphasizing the company's commitment to product innovation[45]. - The company is actively engaged in research and development of new technologies to improve packaging efficiency and sustainability[62]. - The company has developed new products such as high-barrier low-adsorption composite films and high-barrier self-humidifying composite films, which received positive market feedback[37]. Market Position and Strategy - The company focuses on the development and application of high-barrier, low-adsorption, low-migration packaging materials, primarily for the pharmaceutical industry, with a product range that includes soft and hard packaging materials[28]. - The company has established partnerships with over 2,000 clients, including 80% of China's top 100 pharmaceutical companies, solidifying its position as a leading provider of new pharmaceutical packaging materials[34]. - The company is positioned to benefit from the growing demand in the pharmaceutical sector, driven by an aging population and increased healthcare spending in China[34]. - The company plans to enhance its market presence through strategic investments and partnerships, aiming to broaden its sales channels and product range[62]. Risks and Challenges - The company faces significant market competition with over 1,500 players in the domestic pharmaceutical packaging industry, which may impact its market share and profitability[66]. - Raw material price fluctuations pose a risk, as materials like aluminum and petroleum derivatives constitute a large portion of the company's production costs[66]. - The ongoing COVID-19 pandemic presents uncertainties regarding customer orders and project timelines, potentially affecting future business performance[68]. Corporate Governance and Compliance - The company has maintained compliance with environmental regulations, with no administrative penalties related to environmental issues during the reporting period[82]. - The company has not engaged in any major asset or equity sales during the reporting period[57]. - The company has not provided any external guarantees during the reporting period, maintaining a conservative financial policy[94]. Shareholder Information - The company did not distribute cash dividends or bonus shares for the first half of 2021[73]. - The total number of shares before the recent change was 156,529,800, with a decrease of 1,076,550 shares, resulting in a new total of 155,453,250 shares[119]. - The largest shareholder, Lin Wuhui, holds 37.07% of shares, totaling 58,019,999 shares, with a decrease of 500 shares during the reporting period[127].

上海海顺新型药用包装材料股份有限公司 2021 年第一季度报告全文 上海海顺新型药用包装材料股份有限公司 2021 年第一季度报告 2021-028 2021 年 04 月 1 上海海顺新型药用包装材料股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人林武辉、主管会计工作负责人倪海龙及会计机构负责人(会计主 管人员)范云波声明：保证季度报告中财务报表的真实、准确、完整。 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 223,874,529.01 | 155,553,004.86 | 43.92% | | 归属于上市公司股东的净利润（元） | 33,586,697.68 | 14,347,011.84 | 134.10% | | 归属于上市公司 ...